Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
2001-03-12
2002-10-15
Travers, Russell (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
C514S177000, C514S169000, C514S170000
Reexamination Certificate
active
06465446
ABSTRACT:
FIELD OF THE INVENTION
This invention relates to methods and compositions for treating dermatitis.
BACKGROUND
Dermatitis is a chronic inflammatory skin disorder characterized generally by redness, edema, oozing, crusting, scaling, and pruritus. Dermatitis and eczema are often used synonymously and are used synonymously herein, including the claims.
Various types of dermatitis have been classified including contact dermatitis, atopic dermatitis, seborrheic dermatitis (dandruff), nummular dermatitis, pompholyx, psoriasis, generalized exfoliative dermatitis, stasis dermatitis, and localized scratch dermatitis. See, The Merck Manual of Diagnosis and Therapy, 16
th
Edition, Merck & Co. Inc., pp. 2407-2415. As utilized herein, the various types of dermatitis are collectively referenced simply as “dermatitis.”
Atopic dermatitis is a chronic inflammatory skin disorder exhibited by individuals with a hereditary predisposition of a lowered cutaneous threshold to pruritis. Atopic dermatitis is often accompanied by allergic rhinitis, hay fever, and asthma. A primary characteristic of atopic dermatitis is extreme itching, leading to repeated scratching which in turn results in the typical lesions of eczema. Infantile eczema occurs predominantly on the cheeks, which may extend to other areas of the body. Eczema occurring on children, adolescents, and adults is found predominantly on the flexural surfaces, especially on the antecubital and popiteal areas, and on the neck, eyelids, wrists, and behind the ears.
In atopic dermatitis, and eczema in general, immunologically mediated leukocyte infiltration (particularly infiltration of mononuclear cells, lymphocytes, neutrophils, and eosinophils) into the skin significantly contributes to the pathogenesis of these diseases. Chronic eczema also is associated with significant hyperproliferation of the epidermis.
Atopic dermatitis and eczema, if sufficiently severe, can lead to death. Less serious, but uncomfortable and often painful symptoms associated with atopic dermatitis include itching, swelling, redness, blisters, crusting, ulceration, pain, scaling, cracking, hair loss, scarring, or oozing of fluid involving the skin, eye or mucosal membranes.
The need to control atopic dermatitis has led to a search for therapeutic agents that are both safe and effective. Corticosteroids, when administered systemically, are effective in this regard but are associated with significant and potentially dangerous side effects. Topically applied corticosteroids have some efficacy in treating these conditions, but are only partially effective in many instances and have their own significant side effects, including atrophy of tissue, formation of telangiectasia, blanching, and a myriad of systemic effects if significantly absorbed. Other agents with partial utility for treating some of the above conditions include psoralen plus ultraviolet A (PUVA), cyclosporin A, ultraviolet A (UVA) and topical Doxepin, for treatment of the associated symptom of pruritis. However, the risk-to-benefit ratios for these agents are unfavorable for most of the conditions described above.
As a result, there is a significant and very long-standing need to identify new agents with favorable benefit to risk ratios that can be applied topically to prevent, suppress or control atopic dermatitis and its associated symptom of (pruritis).
SUMMARY OF THE INVENTION
The invention is directed to the administration of &Dgr;5-androstene-3&bgr;-ol-7,17 dione and metabolizable precursors thereof, such as &Dgr;5-androstene-3&bgr;-acetoxy-7,17 dione, to treat dermatitis and the associated symptom of pruritis.
REFERENCES:
patent: 5292730 (1994-03-01), Lardy
patent: 5296481 (1994-03-01), Partridge et al.
patent: 5424463 (1995-06-01), Lardy et al.
patent: 5506223 (1996-04-01), Lardy et al.
patent: 5585371 (1996-12-01), Lardy
patent: 5641766 (1997-06-01), Lardy
patent: 5707983 (1998-01-01), Lardy
patent: 5807848 (1998-09-01), Lardy
patent: 5885977 (1999-03-01), Pauza et al.
patent: 5972917 (1999-10-01), Bishop et al.
patent: 6153606 (2000-11-01), Lardy et al.
patent: WO 99/25192 (1999-05-01), None
patent: WO 99/25333 (1999-05-01), None
Malaviya et al., Journal of Molecular Medicine, (Aug. 1998) 76 (9) 617-23.*
de Weck A L., Federation Proceedings, (Apr. 1977) 36 (5) 1742-7.*
Pike et al. Nutrition An Integrated Approach (3rd ED) (1984), p. 553.*
U.S. patent application Ser. No. 09/641,193, Zenk, filed Aug. 2000.
U.S. patent application Ser. No. 09/665,640, Zenk et al., filed Sep. 2000.
U.S. patent application Ser. No. 60/250,227, Zenk et al., filed Nov. 2000.
“Grapeseed Palma Christi Lotion; DHEA Crème Moisturizer with Antioxidants; Citronella Aura Glow Massage Formula; Russian Whit Oil Manufacturer: Heritage Store Category: Skin Care,”Product Alert, May 12, 1997 (Abstract).
“Sweet Dreams Melatonin Night Cream; DHEA Day Cream; Manufacturer: Emerald Pharmaceuticals Catagory: Skin Care,”Product Alert, May 12, 1997 (Abstract).
Berliner, David L., “Biotransformation of Steroids by the Skin,”Advances in Biology of Skin, vol. XII, Pharmacology and the Skin, p. 357-365, 1969.
Berliner, David L. et al., “The Formation of Water Soluble Steroids by Human Skin,”The Journal of Investigative Dermatology, vol. 50, No. 3, p. 220-224, 1968.
Faredin, I. et al., “The Metabolism of [4-14C]5-Androstene-3&bgr;,17&bgr;-Diol by Normal Human Skin in Vitro,”Acta Medica Academiae Scientiarum Hungaricae, vol. 32, p. 139-152, 1975.
Faredin, I. et al., “The in Vitro Metabolism of Dehydroepiandrosterone in the Human Skin,”Acta Medica Academiae Scientiarum Hungaricae, vol. 23, p. 169-180, 1967.
Frost, Phillip,et al., “Metabolism of Estradiol-17&bgr; and Estrone in Human Skin,”The Journal of Investigative Dermatology, vol. 46, No. 6, pp. 584-585, 1966.
Gallegos, A.J., “Transformation and Conjugation of Dehydroepiandrosterone by Human Skin,”The Journal of Clinical Endocrinology and Metabolism, vol. 27, No. 7, p. 1214-1218, Jul. 1967.
Klein, A. et al., “Effect of a non-viral fraction of acquired immunodeficiency syndrome plasma on the vulnerability of lymphocytes to cortisol,”Journal of Endocrinology, vol. 112, No. 2, p. 259-264, Feb. 1987.
Malkinson, Frederick D. et al., “In Vitro Studies of Adrenal Steriod Metabolism in the Skin,”The Journal of Investigative Dermatology, p. 101-107.
Xu, Pengjin et al., “Characterization of Physico-Chemical Properties and Skin Permeability of Dehydroepiandrosterone,”Pharmaceutical Research, vol. 12, No. 9, p. S-273, Sep. 1995 (Supplement).
Jiang S.
Sherrill Michael S.
Travers Russell
LandOfFree
Treatment of dermatitis by the topical application of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of dermatitis by the topical application of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of dermatitis by the topical application of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2969559